Amorfix Test For vCJD Achieves 100% Specificity On 20,000 Blood Donations In France

    -- EP-vCJD(TM) Test 5 Times More Sensitive Than Required By UK Blood
    Transfusion Service --

    TSX: AMF

    TORONTO, June 24 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, today announced it has
tested 20,000 blood donations in France using its EP-vCJD(TM) blood screening
test as part of a large-scale study to demonstrate the feasibility of routine
testing of blood donations for vCJD. At the UK specification of a required
sensitivity of 1:100,000 dilution of vCJD brain, the Amorfix test was 100%
specific with no false positive samples on repeat testing. The test performed
five times better than required as it was still 100% specific at a sensitivity
of 1:500,000 dilution of vCJD brain. At the maximum sensitivity of 1:1,000,000
dilution of vCJD brain, the test was 99.90% specific which exceeds the 99.85%
specificity required by the UK Blood Transfusion Service. The complete
Strasbourg study will be presented today at le Congrès 2009 de la Société
Francaise de Transfusion Sanguine in Strasbourg.
    "France has taken a leading role in assessing the feasibility of testing
routine blood donations for vCJD by establishing the Amorfix test in two major
blood transfusion centers," said Dr. George Adams, Chief Executive Officer of
Amorfix. "The Amorfix test continues to demonstrate its readiness for use by
high-risk nations to conduct prevalence studies to assess the safety of their
blood supply."

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or

    %SEDAR: 00022789E

For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,; Dr. Neil Cashman, Chief Scientific Officer, Amorfix
Life Sciences Ltd., Tel: (778) 994-2626, Fax: (416) 847-6899,

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890